(NASDAQ: IRD) Opus Genetics's forecast annual revenue growth rate of 51.24% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 65.42%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.4%.
Opus Genetics's revenue in 2025 is $10,992,000.On average, 1 Wall Street analysts forecast IRD's revenue for 2025 to be $569,912,302, with the lowest IRD revenue forecast at $569,912,302, and the highest IRD revenue forecast at $569,912,302. On average, 1 Wall Street analysts forecast IRD's revenue for 2026 to be $1,006,102,165, with the lowest IRD revenue forecast at $1,006,102,165, and the highest IRD revenue forecast at $1,006,102,165.
In 2027, IRD is forecast to generate $1,787,059,406 in revenue, with the lowest revenue forecast at $1,787,059,406 and the highest revenue forecast at $1,787,059,406.